Enliven Therapeutics (ELVN) Payables (2019 - 2026)
Enliven Therapeutics (ELVN) posted Payables of $1.6 million for Q1 2026, down 24.04% sequentially from $2.2 million in Q4 2025, and up 4.99% YoY from $1.6 million in Q1 2025.
Enliven Therapeutics (ELVN) Payables (2019 - 2026) Analysis & Trends
Enliven Therapeutics has reported Payables for 8 years, with the latest figure at $1.6 million in Q1 2026.
- Quarterly Payables rose 4.99% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 4.99% YoY) and the FY2025 annual result came in at $2.2 million, up 60.88% from the prior year.
- Payables declined to $1.6 million in Q1 2026 per ELVN's latest filing, from $2.2 million in the prior quarter.
- Over five years, Payables peaked at $5.9 million in Q1 2023 and troughed at $532000.0 in Q4 2023.
- A 5-year average of $2.0 million and a median of $1.6 million in 2025 frame the typical range for Payables.
- The widest YoY moves for Payables: up 211.04% in 2023, down 84.53% in 2023.
- Over 5 years, Payables stood at $3.4 million in 2022, then sank by 84.53% to $532000.0 in 2023, then soared by 152.26% to $1.3 million in 2024, then soared by 60.88% to $2.2 million in 2025, then dropped by 24.04% to $1.6 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $1.6 million, $2.2 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | 371,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 371,000.00 |
| Mar 31, 2026 | 1.64 Mn |
| Dec 31, 2025 | 2.16 Mn |
| Sep 30, 2025 | 1.43 Mn |
| Jun 30, 2025 | 2.35 Mn |
| Mar 31, 2025 | 1.56 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | 2.73 Mn |
| Dec 31, 2023 | 532,000.00 |
| Sep 30, 2023 | 1.49 Mn |
| Jun 30, 2023 | 2.84 Mn |
| Mar 31, 2023 | 5.86 Mn |
| Dec 31, 2022 | 3.44 Mn |
| Sep 30, 2022 | 767,000.00 |
| Jun 30, 2022 | 1.14 Mn |
| Mar 31, 2022 | 1.88 Mn |
| Dec 31, 2021 | 2.36 Mn |
| Sep 30, 2021 | 2.48 Mn |